Rhabdomyolysis in heart transplant patients on HMG-CoA reductase inhibitors and cyclosporine

By Rodrguez J.A.   Crespo-Leiro M.G.   Paniagua M.J.   Cuenca J.J.   Hermida L.F.   Juffe A.   Castro-Beiras A.  

Transplantation Proceedings, Vol. 31, Iss. 6, 1999-09 ,pp. : 2522-2523

Elsevier

Access to resources Recommend Favorite

Early introduction of HMG-CoA reductase inhibitors could prevent the incidence of transplant coronary artery disease

By Kato T.   Tokoro T.   Namii Y.   Kobayashi T.   Hayashi S.   Yokoyama I.   Morimoto S.   Chan M.   Giannetti N.   Hunt S.A.  

Transplantation Proceedings, Vol. 32, Iss. 2, 2000-03 ,pp. : 331-333

Elsevier

Access to resources Recommend Favorite

HMG-CoA Reductase Inhibitors Pravastatin and Simvastatin Inhibit Human B-Lymphocyte Activation

By Rudich S.M.   Mongini P.K.A.   Perez R.V.   Katznelson S.  

Transplantation Proceedings, Vol. 30, Iss. 4, 1998-06 ,pp. : 992-995

Elsevier

Access to resources Recommend Favorite

HMG-CoA Reductase Inhibitors: Effects on Chronic Subacute Inflammation and Onset of Atherosclerosis Induced by Dietary Cholesterol

By  

Current Drug Targets - Cardiovascular & Hematological Disorders, Vol. 5, Iss. 6, 2005-12 ,pp. : 441-453

Bentham Science Publishers

Access to resources Recommend Favorite

The Possible Therapeutic Actions of Peroxisome Proliferator-Activated Receptor (PPAR) Agonists,PPAR&ggr; Agonists,3-Hydroxy-3- Methylglutaryl Coenzyme A (HMG-CoA)Reductase Inhibitors,Angiotensin Converting Enzyme (ACE)Inhibitors and Calcium (Ca)-Antagonists on Vascular Endothelial Cells

By  

Current Drug Targets - Cardiovascular & Hematological Disorders, Vol. 4, Iss. 1, 2004-03 ,pp. : 35-52

Bentham Science Publishers

Access to resources Recommend Favorite